News Room

Interview opportunity: JDRF celebrates the announcement of Dexcom G6 CGM System’s Availability in Canada

JDRF shares the excitement of the type 1 diabetes community around today’s arrival of the Dexcom G6,” said Dave Prowten, President and CEO of JDRF Canada. “While JDRF remains focused on our goal to cure type 1 diabetes, we welcome the arrival of new and innovative technologies like this that help Canadians living with the disease live easier, healthier, safer lives.”

Statement by Dave Prowten, President and CEO JDRF Canada

JDRF has been closely monitoring developments rising from the recent announcement of a “Safe Importation Action Plan” by the United States Department of Health & Human Services (HHS) and the Food and Drug Administration (FDA) to facilitate the importation of drugs that were intended for other markets, specifically Canada.

B.C. youth Samir Dattani to represent Canadians with type 1 diabetes in Washington, D.C.

British Columbia, July 4, 2019 – 16-year-old Samir Dattani, a long-time type 1 diabetes advocate from Vancouver’s Westside-Kerrisdale neighbourhood, is set to join hundreds of delegates from the United States and around the world at Juvenile Diabetes Research Foundation’s 2019 Children’s Congress in Washington, D.C. from July 8 – 10, where he will represent Canadians living with type 1 diabetes (T1D).

JDRF welcomes Disability Advisory Committee’s recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach

JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) First Annual Report, in particular, the DAC’s recommendation that all Canadians receiving life-sustaining therapy should qualify for the Disability Tax Credit (DTC).